摘要
目的探讨莫沙必利联合铝碳酸镁治疗胆汁反流性胃炎(RBG)的疗效及安全性。方法 128例RBG患者分为A组和B组,每组各64例。A组应用莫沙必利联合铝碳酸镁,B组应用莫沙必利联合复方阿嗪米特,疗程均为4周。比较两组患者的临床疗效、各症状评分改变及不良反应。结果 A组的总有效率89.1%,显著高于B组75.0%,差异有统计学意义(P<0.05);治疗后,两组患者的恶心、呕吐、腹痛及腹胀等症状评分均较治疗前显著降低,差异有统计学意义(P<0.05),而A组的各症状评分显著低于B组,差异有统计学意义(P<0.05);A组和B组不良反应发生率分别为9.4%和12.5%,差异无统计学意义(P>0.05)。结论莫沙必利联合铝碳酸镁治疗胆汁反流性胃炎的疗效优于联合复方阿嗪米特,可有效结合反流入胃内的胆酸,减少胆酸的反流。
Objective To comparison the curative effects and safety of combined usage of mosapride combined with hydrotalcite or azintamide for the treatment of patients with bile reflux gastritis （RBG） .Methods A total of 128 cases of RBG patients were randomly divided into group A （64 cases） ,given mosapride combined with hydrotal-cite and group B （64 cases） ,given mosapride combined with azintamide ,respectively .The treatment course was 4 weeks .Clinical effect ,change of symptom scores and side effect were compared .Results The effective rate in group A was 89 .1% ,significantly higher than the 75 .0% in group B （P〈0 .05） .After treatment ,the symptom scores of nausea ,vomiting ,abdominal pain and abdominal distension in the two groups were significantly lower than those be-fore treatment （P〈0 .05） ,and these indicators in group A were decreased more significantly than those in group B （P〈0 .05） .The incidence rates of side effect in group A and group B were 9 .4% and 12 .5% ,without statistical difference （P〈0 .05） .Conclusion Mosapride combined with hydrotalcite could be with better curative effects than mosapride combined with azintamide for treatment of RBG .
出处
《检验医学与临床》
CAS
2014年第8期1046-1047,共2页
Laboratory Medicine and Clinic
